Natera

What a great time this week at the 2025 ACMG Annual Clinical Genetics Meeting in Los Angeles! 💙💚 Thanks to everyone who visited our booth and attended our presentations, including our ACMG Foundation corporate partner insights session on precision medicine across oncology, renal genetics and reproductive health. We're already looking forward to next year in Baltimore, MD! ACMG - American College of Medical Genetics and Genomics Sheetal Parmar Eileen Hoffman, MS, CGC A. Katya Brossart #ACMGMtg25

Congratulations, Jessica Adsit, MS, CGC, on receiving the 2025 ACMG Foundation Genetic Counselor Best Abstract Award from the ACMG - American College of Medical Genetics and Genomics Foundation for Genetic and Genomic Medicine. Jessica was presented this award for her platform presentation, “Next Generation Sequencing in Blastocyst Stage Embryos: Results of over 41,000 Trophectoderm Biopsy Samples,” at the 2025 ACMG Annual Clinical Genetics Meeting in Los Angeles, CA. Attendees can see Jessica present this abstract on March 20 at 12:15 PM PT in Petree Hall C. Jessica said, “Thank you so much to the ACMG Foundation for recognizing the work of myself and my colleagues. I am especially honored to receive an award that highlights the various contributions that genetic counselors make to research and clinical care.” 👏 https://ow.ly/gOUB50VkXQ5 #ACMGMtg25 #GeneticCounselor

The technology Natera has developed is like finding a single blade of grass in 100,000 soccer fields—Finding a single DNA molecule in a regular blood draw from the arm that carries a cancer mutation.

Catch diseases early, treat them early, and lower healthcare costs—That's what integrated risk models are all about. DNA Today

The first patients have begun enrolling in the HEROES clinical trial, which is evaluating the use of Natera’s Signatera MRD test for de-escalation or discontinuation of therapy in metastatic HER2+ breast cancer. Safely discontinuing treatment has been a long-lasting dilemma in this type of breast cancer. With Signatera, we hope oncologists can identify the patients without detectable disease who may be able to avoid additional therapy that can be costly and potentially harmful to their care. Learn more: https://ow.ly/zNns50VeVGb

Genome sequencing costs under 2% of the annual per capita health budget—small cost, massive savings. DNA Today Kira Dineen, MS, LCGC, CG(ASCP)CM https://lnkd.in/dEbfQX7J

ACMG 2025 is around the corner! Join us on March 19 for our session: Precision Medicine across Oncology, Renal Genetics, and Reproductive Health. Genomic testing has traditionally been used for diagnosis. In this session, attendees will learn how results can be used to identify patients who would benefit from further testing and to inform treatment options. Join Natera to learn how genetic testing can enable a personalized approach with the potential to improve outcomes. We will also explore: 🔬How data from molecular residual disease testing can enhance awareness of hereditary cancer testing 🧬The interaction between the genetic causes of kidney disease and targeted therapies 🤰How expansion of prenatal screening improves outcomes through early diagnosis and perinatal treatment options Featuring: John Williams III, MD Director of Reproductive Genetics and Professor of Obstetrics and Gynecology at Cedars-Sinai Medical Center and the David Geffen School of Medicine at UCLA A. Katya Brossart, MS, CGC Manager of Genetics Education & Engagement Organ Health, Natera Eileen Hoffman, MS, CGC Medical Science Liaison, Natera Oncology Moderated by: Sheetal Parmar, MS, CGC SVP Medical Affairs, Natera Women's Health ACMG - American College of Medical Genetics and Genomics Natera Oncology Natera Organ Health Natera Women's Health #Natera #ACMG #ACMGMtg25

Exciting news! Natera CEO Steve Chapman has been appointed to the Board of Directors of the American Clinical Laboratory Association (ACLA). 👏 ACLA advocates for policies that expand access to high-quality clinical laboratory services, improve patient outcomes, and advance the next generation of personalized care. https://ow.ly/Gu3Q50V9rGG

With today’s news that Medicare will cover Signatera for stage I-III non-small cell lung cancer in surveillance, Signatera is now more accessible to patients living with lung cancer – the most lethal and one of the most common forms of cancer in the United States. Signatera test performance and utility in the surveillance setting for stage I-III NSCLC was validated in three independent peer-reviewed studies to support this coverage determination. The body of evidence continues to grow demonstrating Signatera’s value across a broad range of cancer indications and settings. Read more in our latest press release. https://ow.ly/44Jf50V65LQ

Such amazing energy at the Natera Global Sales Meeting a few weeks ago. What a wonderful team with whom to share the message that we’re just getting started. Thank you.